HYDROCORTISONE ACETATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Hydrocortisone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression. It exerts anti-inflammatory, immunosuppressive, and vasoconstrictive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
| Metabolism | Hepatic metabolism via CYP3A4, also reduction by 20-ketosteroid reductases; major metabolites include tetrahydrocortisone and tetrahydrocortisol. |
| Excretion | Renal: ~80% as metabolites (glucuronide and sulfate conjugates) and <1% unchanged; fecal: <5% via biliary elimination. |
| Half-life | Terminal elimination half-life: 1-2 hours for endogenous hydrocortisone; with acetate ester, extended to ~2-4 hours due to slower absorption and hydrolysis. Clinical context: Duration of action exceeds half-life due to intracellular receptor binding. |
| Protein binding | 90-95% bound primarily to corticosteroid-binding globulin (CBG, transcortin) and albumin; hydrocortisone acetate has similar binding profile as free hydrocortisone. |
| Volume of Distribution | 0.3-0.4 L/kg (for hydrocortisone base). Vd is relatively small, consistent with extensive protein binding and limited tissue penetration; distributes into extracellular fluid and poorly into CNS. |
| Bioavailability | Oral: not applicable (acetate form not for oral use); intramuscular: 100% (administered as suspension); topical: minimal systemic absorption (~1-2% with intact skin, higher with damaged skin); rectal: 20-30% (enema preparation). |
| Onset of Action | Intravenous: minutes (as free alcohol); intramuscular: 1-2 hours; topical: variable, typically 3-5 days for anti-inflammatory effect; intra-articular: 1-2 days; rectal (enema): within 2-4 hours. |
| Duration of Action | Intramuscular: 8-12 hours; intra-articular: up to 2-4 weeks; topical: 1-2 weeks with repeated application; rectal: 6-12 hours. Clinical notes: Duration is prolonged with depot formulations due to slow ester hydrolysis. |
| Molecular Weight | 404.5 |
Hydrocortisone acetate is typically administered as a topical, intra-articular, intradermal, or rectal preparation. For intra-articular use, adult dose: 5-50 mg (depending on joint size) every 1-2 weeks. For rectal use, 25 mg (one suppository) twice daily or 1 application of foam or enema (10% or 1% respectively) once or twice daily. For intradermal injection, 1-2 mL (25 mg/mL) into lesion every 1-2 weeks. Note: Systemic dosing is not applicable as it is not used for systemic effects due to low bioavailability.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for topical, intra-articular, or rectal formulations due to minimal systemic absorption. For extensive or prolonged use in renal impairment, monitor for systemic effects (e.g., fluid retention). No specific GFR-based guidelines. |
| Liver impairment | No dosage adjustment required for topical, intra-articular, or rectal formulations due to minimal systemic absorption. In severe hepatic impairment (Child-Pugh C), consider potential for increased systemic exposure if used on large areas or damaged skin; monitor for adverse effects. |
| Pediatric use | Topical: Apply sparingly to affected area once or twice daily. Rectal: Children 2-12 years: 25 mg suppository once daily (or half adult dose depending on formulation). Intra-articular: Not typically recommended; consult specialist. Doses should be based on body surface area and severity; avoid prolonged use. |
| 1st trimester | Topical corticosteroids like hydrocortisone acetate are generally considered low risk in the first trimester when used in small amounts, but systemic use is associated with a small increased risk of orofacial clefts. |
| 2nd trimester | Use minimally sufficient amounts; systemic absorption is low with topical application, but prolonged use may affect fetal growth. |
| 3rd trimester | Use with caution; high doses or prolonged use may lead to fetal adrenal suppression or low birth weight. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Low placental transfer due to rapid metabolism in placenta; however, systemic exposure can lead to measurable levels in fetal circulation. |
■ FDA Black Box Warning
None
| Common Effects | adrenal insufficiency |
| Serious Effects |
Untreated bacterial, fungal, or viral skin infectionsHypersensitivity to hydrocortisone or any component
| Precautions | Systemic absorption from topical application may produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Use with caution in patients with diabetes, osteoporosis, hypertension, congestive heart failure, or tuberculosis., May mask signs of infection; increased susceptibility to infections., Live or attenuated vaccines contraindicated with high doses., Abrupt withdrawal may cause adrenal insufficiency., Pediatric patients may be more susceptible to systemic toxicity. |
| Food/Dietary | No significant dietary restrictions. However, because corticosteroids can increase potassium excretion and fluid retention, consider a diet adequate in potassium (e.g., bananas, oranges, spinach) and low in sodium (avoid high-salt processed foods) if on prolonged systemic therapy. Grapefruit juice may alter metabolism of corticosteroids, but interaction is minimal for hydrocortisone; caution with large quantities. |
Loading safety data…
| Geriatric use |
| Use with caution due to increased risk of skin atrophy with topical use. Intra-articular: Use lowest effective dose. Rectal: No specific adjustment, but monitor for fluid retention and electrolyte imbalance. Consider age-related renal and hepatic function decline. |
| Breastfeeding | Hydrocortisone acetate is excreted into breast milk in small amounts, but doses from topical use are unlikely to affect the infant. However, avoid applying to the breast area to prevent infant ingestion. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio ~1.3-3.4) with systemic use. Second and third trimesters: Possible fetal growth restriction, adrenal suppression, and oligohydramnios with prolonged high-dose therapy. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal growth ultrasound if prolonged use. Newborns exposed in utero should be monitored for adrenal insufficiency. |
| Fertility Effects | No direct impairment of fertility reported. Indirect effects from underlying condition (e.g., autoimmune disease) may affect fertility. |
| Clinical Pearls | Hydrocortisone acetate is a short-acting corticosteroid with low potency. For topical use, avoid application on infected lesions unless anti-infective therapy is co-administered. Systemic absorption from topical application can occur, especially with prolonged use over large areas, under occlusion, or on denuded skin. For intra-articular injection, use strict aseptic technique and do not inject into unstable joints. Adrenal suppression may occur with long-term use or high doses; taper therapy to withdraw. Administer oral doses with food or milk to reduce GI irritation. |
| Patient Advice | Use exactly as prescribed; do not use more often or longer than directed. · Do not apply to broken skin, open wounds, or infected areas without medical advice. · Wash hands before and after application unless treating hands. · Avoid contact with eyes, mouth, or genital area; flush with water if contact occurs. · If using for a skin condition, apply a thin layer and rub in gently; do not cover with bandages unless instructed. · Tell your doctor if your condition does not improve after 2 weeks. · Inform your doctor about all other medications you use, including over-the-counter products and supplements. · For oral forms: take with milk or food to prevent stomach upset. · Do not stop taking abruptly without consulting your doctor; dose may need to be tapered. · Report any signs of infection, skin thinning, or allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing). |